Integrating Molecular Genetic Microbiome Analysis Into Clinical Practice: From Lab Test to Personalized 3P/4P Medicine
Modern healthcare is undergoing a fundamental transformation. Traditional symptomatic medicine, built on averaged standard protocols ('one diagnosis — one treatment scheme'), increasingly shows its limits with chronic, relapsing and multi-organ pathologies. Rising IBS, autoimmune disease, metabolic syndrome, atopic dermatitis, chronic fatigue and neuroendocrine disorders demand clinicians seek root causes rather than mask symptoms.
The answer is 3P/4P medicine (predictive, preventive, personalized and participatory). At its center stands the human microbiome — a complex metabolic-immune organ of trillions of microorganisms regulating epithelial barrier integrity, neurotransmitter synthesis, the maturation of 80% of immunocompetent cells, and chronic inflammatory cascades.
For modern clinics, medical centers and private practices, adopting omics technologies — molecular genetic microbiome analysis in particular — is no longer scientific exotica. It is a powerful clinical instrument raising treatment efficacy, cutting relapse rates and building strong patient loyalty.
In this article we examine the methodological and biotech aspects of integrating microbiome testing into a medical facility's workflow, and reveal B2B partnership opportunities with Ediens.
1. Next-Generation Sequencing (NGS) vs Outdated Routine Methods
For a long time, classic microbiological culture (dysbiosis stool culture) remained the only available clinical method for assessing flora. Yet from modern molecular biology's standpoint this method is outdated and uninformative, for several reasons:
1. The culturability problem: over 95–98% of large-intestine microorganisms are obligate anaerobes. They die on contact with air oxygen and fundamentally do not grow in Petri dishes on standard media.
2. Fragmentary data: culture assesses only a tiny share of aerobic species (mostly E. coli, enterococci, staphylococci and yeasts), painting a false picture of the whole ecosystem.
Advantages of NGS (16S rRNA sequencing):
Next-generation sequencing (NGS) of the marker 16S rRNA gene directly extracts and decodes the DNA of absolutely all microorganisms in a biological sample, regardless of their viability under artificial conditions.
A microbiome DNA test gives the practicing physician 150+ clinical and ecological parameters:
Alpha diversity (Shannon and Pielou indices): a fundamental gauge of ecosystem resilience to external shocks, antibiotics and infections.
Phyla ratios (Firmicutes/Bacteroidetes, Proteobacteria): a biomarker of metabolic syndrome, insulin resistance and systemic-inflammation predisposition.
Key protective strain titers (key drivers): full assessment of Akkermansia muciniphila (mucus-barrier guardian), Faecalibacterium prausnitzii (chief butyrate producer), Bifidobacterium spp. and Lactobacillus spp.
Pathobiont and putrefactive flora analysis: precise identification of opportunistic enterobacteria, clostridia, sulfate-reducing bacteria and fungi.
Metabolic and functional potential: assessing microbiota capacity to synthesize short-chain fatty acids (butyrate, acetate, propionate) and vitamins, metabolize bile acids and accumulate pro-atherogenic TMAO.
2. The Step-by-Step Patient Journey: How Clinic Integration Works
Integrating microbiome analysis into clinical practice requires no expensive lab equipment purchases or in-house bioinformaticians. The process follows a clear, seamlessly tuned algorithm:
1. Initial visit and screening.
2. Biosample collection (Home/Clinic Kit).
3. NGS sequencing at the Ediens laboratory.
4. Automated SaaS interpretation (EdiensUniCode).
5. Personalized protocol generation (Biocode4U).
6. Physician consultation and targeted therapy.
Stage 1. Screening and test indications
The physician (gastroenterologist, dermatologist, endocrinologist, nutritionist, reproductologist or preventive-medicine specialist) identifies test indications:
Chronic GI disorders (IBS, SIBO, chronic constipation, bloating).
Dermatological pathologies (acne, rosacea, atopic dermatitis, psoriasis).
Metabolic disorders (obesity, insulin resistance, metabolic syndrome).
Astheno-neurotic states, chronic fatigue, sleep disorders, PTSD.
Pregnancy preparation or recovery after prolonged antibiotics.
Stage 2. Convenient biosample collection
The patient receives a branded collection kit with a special preserving buffer stabilizing bacterial DNA at room temperature. Collection happens at the clinic or at home by the patient; courier logistics to the lab are provided.
Stage 3. Bioinformatic processing and automated clinical report
The biggest barrier for practitioners is interpreting 'raw' omics data. Ediens solves this with access to the EdiensUniCode (BioQuantum) cloud platform.
AI algorithms process DNA-sequencing results in seconds, correlate them with reference databases, and generate a ready, visual, structured report for doctor and patient.
Stage 4. Building the personalized prescription protocol
Based on detected shift deviations, the platform automatically calculates:
1. Microbiome Nutrition Plan (Biocode4U): an individual diet of local and fermented foods, with plant ingredients calculated as prebiotics for the patient's deficient bacteria.
2. Targeted pharmabiotic correction scheme: precise selection of proprietary therapeutic pharmabiotics to suppress inflammation and heal the gut barrier.
3. Clinical Value Across Specialties
Microbiome DNA testing substantially expands the diagnostic and therapeutic arsenal of diverse specialists:
A. Gastroenterology
Differentiates functional disorders from hidden inflammation, detects butyrate-producer deficit in ulcerative colitis, builds personalized IBS diet therapy and heals the mucus barrier — eliminating leaky gut syndrome.
B. Dermatology and aesthetic medicine
Reveals the gut–skin axis pathogenesis. Eliminates systemic endotoxemia (LPS leaking into blood) behind recurring acne, rosacea and eczema. Complemented by custom probiotic cosmetics (BioMe Cosmetics soap).
C. Endocrinology and metabolomics
Detects microbial drivers of insulin resistance, assesses Firmicutes/Bacteroidetes ratios, and regulates short-chain fatty acid synthesis influencing glucagon-like peptide-1 (GLP-1) secretion and satiety.
D. Neurology, psychiatry and anti-stress medicine
Assesses the gut–brain axis. Detects deficits of GABA- and serotonin-precursor-synthesizing bacteria — physiologically lowering cortisol, normalizing sleep and supporting the nervous system in PTSD and burnout.
E. Gynecology and urology
Assessing urogenital and gut microbiomes stops recurring bacterial vaginosis, candidiasis, cystitis and prostatitis by restoring mucosal colonization resistance.
4. The Ediens B2B Biotech Ecosystem for Clinics and Partners
The Ukrainian BioTech/MedTech company Ediens, founded under the scientific leadership of Doctor of Biological Sciences, Professor Nadiya Volodymyrivna Boyko, builds on more than 35 years of fundamental research in molecular microbiology, immunology and metabolomics. The company officially represents the European Association for Personalized Medicine (EPMA) and owns 13+ patented proprietary strains.
Ediens offers medical centers, clinics and private physicians a turnkey B2B partnership:
1. Molecular genetics laboratory and logistics
Supplying clinics with collection kits, full-cycle 16S rRNA NGS sequencing on modern platform facilities, and strict quality control of lab stages.
2. 'Shopify for Doctors' cloud platform (EdiensUniCode SaaS)
Physicians get a personal dashboard in the cloud system. The platform auto-interprets DNA results, generates convenient visual charts, issues a ready clinical report and calculates a personalized Microbiome Nutrition Plan.
3. Targeted clinical pharmabiotics line (BioMeCombi 10+1)
Supplying clinics with highly effective new-generation therapeutic pharmabiotics carrying high working concentrations of live clinically validated strains (10⁸ to 10¹⁰ CFU/g):
'My Second Brain. Gut Microbiome': portioned sachets for fast motility normalization, fermentation suppression and mucosal healing.
'Metabolic Antistress': a psychobiotic based on Lactobacillus plantarum IMB B-7414 for cortisol reduction and sleep restoration.
'My Sexual Health': for urogenital microbiome recovery.
'Profilaktor': a patented kids' pharmabiotic (Patent UA 93301) protecting kids' digestion and immunity.
4. Innovative service: individual microbiota bank (Microbiota Bank)
A unique biotech service for your clinic's patients — cryopreservation of their own beneficial autoprobiotic strains. Biological insurance for microbiome recovery after antibiotics or surgery.
5. Flexible B2B cooperation models
Affiliate & Physician Referral Program: rewarding partner compensation for doctors and clinics referring diagnostics.
White Label / Co-Creation: report branding and exclusive co-developed products under your clinic's brand.
Ediens Academy: systematic physician training and upskilling — webinars, masterclasses, complex clinical case reviews.
Conclusions
Integrating microbiome testing into clinic practice is a pronounced technological and economic step forward. Ediens molecular genetic diagnostics and personalized protocols lift a medical center to the cutting edge of 3P/4P medicine — ensuring high treatment precision, expanding high-margin services and winning unquestionable patient trust!
Quick questions and answers (Q&A)
1. How does microbiome sequencing (NGS) differ from classic culture — and why does it matter to a doctor?
Classic culture detects only 1–5% of aerobic bacteria able to grow in a Petri dish. NGS sequencing (16S rRNA) analyzes the DNA of absolutely all microorganisms, including anaerobes (over 95% of microbiota). This gives the physician the full picture of alpha diversity, phyla ratios, protective-strain titers (Akkermansia, Faecalibacterium) and functional metabolic risks.
2. Must a doctor train in bioinformatics to work with the test?
No. The EdiensUniCode (BioQuantum) cloud platform takes all bioinformatic analysis on itself. It automatically processes 'raw' genetic data and issues a visual, easily readable clinical report with ready nutrition (Microbiome Nutrition Plan) and targeted-pharmabiotic recommendations.
3. How long does the journey from biosample to ready report take?
The full laboratory and bioinformatic cycle of NGS DNA sequencing plus report generation on the Ediens platform typically takes 14 to 21 business days — matching international quality omics-diagnostics standards.
4. What economic and reputational gains does an Ediens B2B partnership bring a clinic?
The clinic gains a new revenue stream from high-margin diagnostics and targeted-pharmabiotic sales, raises patient LTV through repeat 30–90-day monitoring tests, and positions itself as an innovative preventive and 3P/4P-medicine center.
Comments